Troy Bremer

Troy Bremer is a prominent figure in the healthcare and biotechnology sectors, currently serving as the Chief Scientific Officer (CSO) at Metronom Health. He has held this position since the company's inception and has played a crucial role in its development and strategic direction. His tenure at Metronom Health lasted until May 2023, where he was instrumental in advancing innovative healthcare solutions related to cancer diagnostics.

Educational Background

Troy Bremer holds a Bachelor’s Degree in Aerospace Engineering from the University of Arizona (1986-1991) and furthered his education at the University of California, San Diego, where he earned both a Master of Science (1991-1995) and a Ph.D. in Bioengineering (1995-1999) .134

Professional Experience

Before his role at Metronom Health, Bremer was involved in various capacities that leveraged his expertise in engineering and bioinformatics:

• Director of Research and Development at Windy Hill Medical Inc. (2008-2009)
• Director of Informatics at Prediction Sciences (2003-2008)
• Senior Computational Scientist at LION bioscience (2001-2003)

His extensive experience includes developing diagnostic tools and conducting research that integrates machine learning with molecular biology, particularly focusing on oncology .256

Contributions to Healthcare

Bremer is known for his work on the DCISionRT test, which combines molecular biology with artificial intelligence to assess the benefits of radiation therapy for patients with ductal carcinoma in situ (DCIS) breast cancer. His research has led to numerous publications and patents, showcasing his commitment to improving patient outcomes through innovative diagnostic solutions .45

In summary, Troy Bremer's career is marked by a blend of engineering expertise and a deep commitment to advancing healthcare through scientific innovation, making him a key player in the field of cancer diagnostics.